The Latest Breaking News from LOGC

The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ:LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatric methylmalonic acidemia patients.  Methylmalonic acidemia is an inherited disorder in which the body cannot process certain proteins and fats (lipids) properly. The FDA acknowledged that…

According to Benzinga Pro data, during Q4, LogicBio Therapeutics (NASDAQ:LOGC) posted sales of $2.03 million. Earnings were up 11.02%, but LogicBio Therapeutics still reported an overall loss of $9.06 million.

Over the past 3 months, 4 analysts have published their opinion on LogicBio Therapeutics (NASDAQ:LOGC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.